Wednesday, July 2, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > CEO Life > Food > Baxter to divest biopharma solutions unit for $4.25 billion

Baxter to divest biopharma solutions unit for $4.25 billion

in Food, Health, News
5 questions facing the pharma industry in 2023
Share on LinkedinShare on WhatsApp

Baxter International Inc said on Monday a private-equity group, which includes Warburg Pincus and Advent International, has agreed to buy its biopharma solutions unit for $4.25 billion.

Medical device makers such as Baxter have been grappling with supply-chain shortages that began during the pandemic, while rising costs of raw materials, labor and transportation added more pressure.

Baxter announced its intent to explore alternatives for its biopharma solutions business and spin off its kidney care units in January, stating the restructuring will allow greater alignment with the company’s manufacturing footprint.

Reuters was first to report the private-equity consortium was in the lead to acquire Baxter’s biopharma solutions business.

Baxter will receive after-tax proceeds of $3.4 billion, which it intends to use to pay down the debt the company incurred when it purchased medical device maker Hill-Rom Holdings for $10.5 billion in 2021. Baxter had a market value of $19 billion and total debt of $16.6 billion, as of December 31.

Baxter estimates the transaction will reduce the company’s earnings by about $0.10 per share in the fourth quarter.

The medical device maker’s biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as vaccines.

Through the deal, Advent International and Warburg Pincus will gain access to Baxter BioPharma solutions’ manufacturing facilities and about 1,700 employees in Bloomington, Indiana and Halle, Germany.

Private-equity firms have increasingly been investing in the drug development sector, which was deemed as risky, by coming up with deals that compensate them for the uncertainty involved.

Through the deal with Baxter, which is expected to close in the second half of 2023, the private-equity firms hope to strengthen their presence in the contract drug manufacturing space.

By Khushi Mandowara and Bhanvi Satija / Reuters

Tags: biomedical engineeringBiotechPharmacueticalUnited States

Related Posts

Hyundai and Kia to adopt Tesla EV chargers
News

Tesla stock rises as company reports steep sales decline

‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured
News

‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured

Del Monte Foods files for bankruptsy
News

Del Monte Foods files for bankruptsy

US job availability drops to new two-year low
News

Jobs report shows unexpected increase

“Big Beautiful Bill” all-nighter divides Senate
News

“Big Beautiful Bill” all-nighter divides Senate

Musk-Trump tensions escalate
News

Musk-Trump tensions escalate

Hyatt sells Playa portfolio for $2 billion
News

Hyatt sells Playa portfolio for $2 billion

TikTok’s day in court arrives
News

Trump awaits China’s approval for TikTok buyer group

Buffett: AI scams are the next big ‘growth industry’
News

Philanthropist Warren Buffett donates $6 billion in shares

Sunscreens and SPF: Which ones actually work and what to look for
Health

Sunscreens and SPF: Which ones actually work and what to look for

No Result
View All Result

Recent Posts

  • Nasdaq’s New Survey Reveals: Next-Gen Investors Embrace Advanced Technology ETFs
  • Blackstone’s Jon Gray on Strategic Discipline, AI, and Entrepreneurial Leadership
  • Tesla stock rises as company reports steep sales decline
  • ‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured
  • Del Monte Foods files for bankruptsy

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.